众生药业：公司将推进RAY1225治疗代谢相关脂肪性肝炎（MASH）的项目工作

Core Viewpoint - The company is advancing its RAY1225 project for the treatment of Metabolic Associated Steatotic Liver Disease (MASH) based on overall research and development progress and strategies, while adhering to relevant guidelines [1] Group 1 - The company responded to investor inquiries on August 7 regarding the progress of its RAY1225 project [1] - The company emphasizes the importance of aligning project work with overall development strategies and guidelines [1] - The company commits to fulfilling its information disclosure responsibilities in accordance with disclosure rules [1]